Business Context and Reporting Period
Company: Zimmer Biomet Holdings, Inc. (ZBH)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Year ended December 31, 2025
Business Overview: A global medical technology leader designing, manufacturing, and marketing orthopedic reconstructive products, sports medicine, biologics, extremities, trauma, craniomaxillofacial, and thoracic products, along with digital and robotic technologies. The company operates through three segments: Americas, Europe/Middle East/Africa (EMEA), and Asia Pacific.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Net Sales | $8,231.5 million | $7,678.6 million |
| Operating Profit | $1,098.1 million | $1,285.7 million |
| Net Earnings | $705.1 million | $903.8 million |
| Diluted EPS | $3.55 | $4.43 |
| Operating Margin | 13.3% | 16.7% |
| Effective Tax Rate | 15.1% | 12.7% |
| Cash Flow from Operations | $1,697.1 million | $1,499.4 million |
| Total Debt | $7,519.1 million | $6,204.6 million (approx.) |
| Cash and Equivalents | $591.9 million | $525.5 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 7.2% year-over-year, driven by the acquisition of Paragon 28 (contributing 2.5% growth), market growth, new product introductions, and a recovery from prior-year operational challenges related to ERP implementation.
- Profitability Decline: Net earnings decreased 22% to $705.1 million. This decline was primarily due to:
- Inventory and instrument charges of approximately $170 million related to product lines intended for discontinuance.
- Acquisition-related costs for Paragon 28 and Monogram Technologies Inc.
- Higher interest expense due to increased debt levels.
- U.S. tariffs and higher performance-related compensation.
- Margin Compression: Gross margin decreased from 63.8% in 2024 to 61.6% in 2025, impacted by inventory charges, tariffs, and inventory step-up costs from acquisitions.
- Segment Performance:
- Americas: Sales up 7.3%; Operating profit margin decreased to 51.4% (from 53.7%) due to lower-margin Paragon 28 sales and higher manufacturing costs.
- EMEA: Sales up 7.0%; Operating profit margin decreased to 32.5% (from 35.1%).
- Asia Pacific: Sales up 5.5%; Operating profit margin decreased to 35.5% (from 38.7%) due to higher bad debt expense and manufacturing costs.
Guidance, Outlook, and Risks
2026 Outlook
- Sales Growth: Expected year-over-year net sales growth of 2.5% to 4.5%. Drivers include market growth, new products, and the Paragon 28 acquisition (estimated 1.0% contribution until April 2026). Foreign currency is expected to have a 0.5% positive impact.
- Operating Profit: Expected to increase compared to 2025 due to higher sales, fixed cost leverage, restructuring savings, and the non-recurrence of certain inventory charges. This may be offset by inflation, U.S. commercial channel investments, higher interest expense, and a higher effective tax rate.
Key Risks and Contingencies
- Acquisition Integration: Risks associated with integrating Paragon 28 and Monogram, including potential failure to realize anticipated benefits or synergies.
- Go-to-Market Transformation: Ongoing conversion of the U.S. sales force from independent agents to employees and changes in China's distribution network pose risks of operational disruption, loss of sales personnel, and litigation.
- Regulatory and Tax:
- IRS proposed adjustments for tax years 2013–2019 could result in significant additional tax expense (approx. $312 million for 2016–2019) if not successfully defended.
- Implementation of OECD Pillar 2 global minimum tax rules.
- Supply Chain and ERP: Previous ERP implementation caused disruptions in 2024; future system updates or supply chain interruptions remain a risk.
- Legal Proceedings: Accrued litigation liabilities were $136.2 million as of December 31, 2025. Specific risks include distributor disputes in China and product liability claims.
Investor Verification Checklist
- Inventory Charges: Verify the magnitude and timing of the $170 million inventory/instrument charge related to discontinued product lines and its impact on future margins.
- Acquisition Synergies: Monitor the integration progress of Paragon 28 and Monogram to ensure projected revenue and cost savings are realized.
- Tax Disputes: Track the status of IRS audits for tax years 2013–2019, particularly the potential $312 million exposure for 2016–2019.
- Sales Force Transition: Assess the impact of the U.S. sales force conversion and China distribution changes on sales continuity and customer relationships.
- Debt Servicing: Review the company's ability to service its $7.5 billion debt load, particularly given the increase in interest rates and the maturity of $587.1 million in current debt in 2026.
- Restructuring Execution: Confirm the realization of the estimated $175 million in annual pre-tax operating expense reductions from the 2025 Restructuring Plan by 2027.